Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28844
Title: First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.
Austin Authors: John, Thomas ;Sakai, Hiroshi;Ikeda, Satoshi;Cheng, Ying;Kasahara, Kazuo;Sato, Yuki;Nakahara, Yoshiro;Takeda, Masayuki;Kaneda, Hiroyasu;Zhang, Helong;Maemondo, Makoto;Minato, Koichi;Hisada, Takeshi;Misumi, Yuki;Satouchi, Miyako;Hotta, Katsuyuki;Li, Ang;Oukessou, Abderrahim;Lu, Shun
Affiliation: Austin Health
Bristol Myers Squibb, 3551 Lawrenceville Road, Princeton, NJ, USA
Saitama Cancer Center, 780, Komuro, Ina, Kitaadachi District, Saitama, 362-0806, Japan
Kanagawa Cardiovascular and Respiratory Center, 6 Chome-16-1 Tomiokahigashi, Kanazawa Ward, Yokohama, Kanagawa, 236-0051, Japan
Jilin Cancer Hospital, No. 1018 Huguang Road, Changchun, 130012, China
Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan
Kobe City Medical Center General Hospital, 2-1-1, Minatojima Minamimachi, Chuo Ward, Kobe, Hyogo, 650-0047, Japan
Kanagawa Cancer Center, 2 Chome-3-2 Nakao, Asahi Ward, Yokohama, Kanagawa, 241-8515, Japan
Kindai University Hospital, 377-2 Onohigashi, Osakasayama, Osaka, 589-8511, Japan
Osaka City University Hospital, 1 Chome-5-7 Asahimachi, Abeno Ward, Osaka, 545-8586, Japan
Tangdu Hospital, Xinsi Road, Baqiao District, Xi'an, 710038, Shaanxi, China
Iwate Medical University Hospital, 2-1-1 Idaidori, Yahaba-cho, Shiwa District, Iwate, 028-3695, Japan
Gunma Prefectural Cancer Center, 617-1 Takahayashinishi-cho, Ota-shi, Gunma, 373-8550, Japan
Gunma University Hospital, 3 Chome-39-15 Showamachi, Maebashi, Gunma, 371-8511, Japan
Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawa Nishimachi, Kanagawa Ward, Yokohama, Kanagawa, 221-0855, Japan
Hyogo Cancer Center, 13-70 Kita-Oji, Akashi, Hyogo, 673-8558, Japan
Okayama University Hospital, 2 Chome-5-1 Shikatacho, Kita Ward, Okayama, 700-0914, Japan
Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 West Huaihai Road, Shanghai, China
Issue Date: Apr-2022
Date: 2022-02-19
Publication information: International Journal of Clinical Oncology 2022; 27(4): 695-706
Abstract: CheckMate 9LA, a phase 3, randomized, open-label study in first-line advanced non-small cell lung cancer (NSCLC), showed significantly improved overall survival (OS) with nivolumab plus ipilimumab combined with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles). We present results for the Asian subpopulation enrolled in Japan and China. Patients aged ≥ 18 years with treatment-naive, histologically confirmed stage IV or recurrent NSCLC, Eastern Cooperative Oncology Group performance status 0-1 and no sensitizing EGFR/ALK mutations were randomized 1:1 to nivolumab [360 mg every 3 weeks (Q3W)] plus ipilimumab (1 mg/kg Q6W) combined with chemotherapy (Q3W for 2 cycles), or chemotherapy alone (Q3W for 4 cycles). Primary endpoint was OS; secondary endpoints included progression-free survival (PFS) and objective response rate (ORR). Twenty-eight patients received nivolumab plus ipilimumab combined with chemotherapy and 30 received chemotherapy. At a minimum follow-up of 12.7 months, median OS was not reached with nivolumab plus ipilimumab combined with chemotherapy versus 13.3 months with chemotherapy [hazard ratio (HR) 0.33; 95% confidence interval (CI) 0.14-0.80]. Median PFS was 8.4 versus 5.4 months (HR 0.47; 95% CI 0.24-0.92) and ORR was 57% versus 23%, respectively. Grade 3-4 treatment-related adverse events were observed in 57% versus 60% of patients, respectively. Consistent with results in the all randomized population, nivolumab plus ipilimumab combined with chemotherapy improved efficacy in the Asian subpopulation versus chemotherapy alone and had a manageable safety profile, supporting its use as first-line treatment for advanced NSCLC in Asian patients.
URI: https://ahro.austin.org.au/austinjspui/handle/1/28844
DOI: 10.1007/s10147-022-02120-0
ORCID: 0000-0003-3399-5342
Journal: International Journal of Clinical Oncology
PubMed URL: 35182247
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35182247/
Type: Journal Article
Subjects: Asia
Immunotherapy
Ipilimumab
Japan
Nivolumab
Non-small cell lung cancer
Appears in Collections:Journal articles

Show full item record

Page view(s)

16
checked on May 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.